Key Highlights

● uniQure traded near $25 on Tuesday, September 29, 2026, after even steeper declines in premarket trading.

● High-dose patients showed slower disease progression at four years, but the result missed statistical significance and was smaller than before.

● The FDA had said 36-month data would underpin uniQure's Biologics license application, putting its regulatory path in focus.

● ClearPoint Neuro, whose platform administers AMT-130, tumbled in sympathy, while Iovance and Summit soared elsewhere in biotech.

uniQure's long-awaited update on its Huntington's disease gene therapy landed with a thud on Tuesday, September 29, 2026. The company released 48-month data from its Phase I/II study of AMT-130, and the shares collapsed. uniQure (NASDAQ:QURE) traded at about $25 during the session after even steeper declines in premarket trading, with a sharp drop at the open and a stock deeply lower at midday.

What the Data Showed

AMT-130, also known as ifezuntirgene inilparvovec, is a gene therapy given as a single administration, and ClearPoint Neuro's navigation and delivery platform is used to administer it. High-dose patients showed a slowing of disease progression on the composite cUHDRS scale at four years, but that result was not statistically significant, and the slowing was smaller than the company had reported at 36 months.

Patients also showed slowing on the TFC functional measure. The study compared patients with an external control group, and much of that external-control data was missing. The FDA had said 36-month data would underpin uniQure's biologics license application, the formal request for approval.

The Company's Case

uniQure's management argued the results remain encouraging. Its chief medical officer, Walid Abi-Saab, said four years after a single administration the therapy continues to show meaningful slowing of disease progression. Chief executive Matt Kapusta said the trends seen in the data are positive and meaningful for patients, adding that the comparator increasingly reflected a healthier population than at baseline, a bias that cuts against AMT-130, not for it.

Lessons for Gene Therapy Investors

The episode highlights the risks that come with gene therapies for slow-moving neurological diseases. Trials are small, results take years, and randomized placebo-controlled studies can be hard to run for one-time therapies. That puts heavy weight on external control groups, whose quality can shape how investors and regulators read the results. The selloff also spread to suppliers, as ClearPoint Neuro (NASDAQ:CLPT) tumbled in sympathy. One report noted that the treatment failed to achieve statistical significance on a primary clinical measure at 48 months, despite showing dose-dependent slowing.

A Sector of Extremes

Iovance Biotherapeutics soared after raising Revenue guidance, and Summit Therapeutics surged on a $2 billion AstraZeneca investment, while healthcare stocks overall declined at midday. The S&P 500 closed at 7,670.84, down 12.85 points, and the Dow Jones Industrial Average closed at 51,349.92, down 131.59 points. The Nasdaq Composite ended little changed at 26,797.54. The 30-year Treasury Yield reached its highest level since 2002, and the 10-year touched its highest in roughly two decades. Consumer confidence dropped to 81.9 from 88.6, the lowest since 2014, according to the Conference Board.

The Regulatory Road From Here

Investors will look for further detail from uniQure on its regulatory discussions and the timing of any application, as well as fuller data presentations. On the macro calendar, August PCE Inflation and the third GDP estimate arrive Wednesday, September 30, the September jobs report follows Friday, October 2, and the Fed meets October 27 to 28.